Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced Soft Tissue Sarcoma
NCT03104335Phase 2Withdrawn
- Sponsor
- Peking University People's Hospital
- Start
- Apr 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in soft tissue sarcoma (STS), sponsored by Peking University People's Hospital. Planned start Apr 2017; status: withdrawn.
02
Drugs
Rivoceranib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03104335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03104335.